FDA safety review remains the next decisive step In the ongoing federal dispute over mifepristone, a judge emphasized that the Food and Drug Administration must complete a safety review before further restrictions can be considered. That requirement matters because mifepristone is a key medication…
Continue reading...
Continue reading...